Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1829 of 6351
-
New drug INCA33890 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowTo evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Heart rhythm device under the microscope: new study tracks Long-Term safety
Disease control OngoingThis post-approval study (PAS) is designed to provide continued clinical evidence to confirm the long-term safety and effectiveness of the FlexAbilityTM Ablation Catheter, Sensor EnabledTM (FlexAbility SE) for the treatment of ventricular tachycardia in a post-market environment.…
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for Crohn's: experimental drug targets gut inflammation
Disease control OngoingThis Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Parkinson's vaccine trial aims to slow disease progression
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease.
Phase 2 • Sponsor: AC Immune SA • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
When to boost? new trial seeks best COVID-19 shot timing for vulnerable patients
Knowledge-focused Recruiting nowIt is important people receiving immunosuppressive therapy are provided with the best protection against COVID-19 because they are at greater risk of severe illness should they become infected. As severe immunosuppression can reduce the efficacy of COVID-19 vaccination, doctors a…
Phase 3 • Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Could a cancer drug fix blood cell problems after transplant?
Disease control OngoingThe purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New stroke drug shows promise in recovery trial
Disease control CompletedThis is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501 low-dose twice a day, or matching placebo for 24 weeks…
Phase 2 • Sponsor: Moleac Pte Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Hormone cocktail shows promise for rare salivary cancer
Disease control OngoingThis phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unre…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for tough leukemias: experimental drug LBS-007 enters human testing
Disease control Recruiting nowThe most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highes…
Phase 1/2 • Sponsor: Lin BioScience, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Magic mushroom compound tested for OCD in small trial
Symptom relief OngoingThis study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's t…
Phase 1 • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Could a weight-loss drug also shield kidneys? new study explores retatrutide for CKD patients.
Disease control CompletedThe main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could half the usual steroid dose protect preterm babies just as well?
Disease control Recruiting nowAntenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome. The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 …
Phase 4 • Sponsor: McMaster University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Poop pills or scope: can donor stool tame ulcerative colitis?
Disease control By invitation onlyThis study aims to perform fecal microbiota transplantation (FMT) and analyze its effects in selected patients aged between 10 and 80 years who have been diagnosed with ulcerative colitis and have been receiving treatment for more than three months at Seoul National University Ho…
Phase 2/3 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:38 UTC
-
New Pill-Infusion combo takes on Hard-to-Treat cancers
Disease control OngoingThis is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.
Phase 1/2 • Sponsor: Fujian Haixi Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Can a simple Post-Discharge program lift depression and boost Self-Care in heart failure patients?
Disease control CompletedThis randomized controlled trial aims to evaluate the effects of a structured transitional care program on depression, self-efficacy, and self-care behaviors in patients with heart failure. Outcomes will be assessed before discharge and at 1 and 3 months after discharge.
Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Hidden malaria: treating Low-Level infections may boost Kids' health
Disease control CompletedThis trial will assess the long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a common arthritis drug tame chikungunya joint pain?
Disease control OngoingMARCH is the first randomized, double-blind, placebo-controlled evaluation of the efficacy and pathologic mechanism determined by synovial biopsy of 6 months of methotrexate (n=100) versus placebo (n=50) therapy for chronic chikungunya (CHIKV) arthritis in Colombia with the optio…
Phase 3 • Sponsor: George Washington University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pacing method may improve heart failure treatment after ablation
Disease control OngoingAtrioventricular node ablation (AVNA) with biventricular (BiV) pacemaker implantation is a feasible treatment option in patients with symptomatic refractory atrial fibrillation and heart failure. However, conduction system pacing (CSP) modalities, including His bundle pacing and …
Sponsor: University Medical Centre Ljubljana • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Blood test clues could sharpen cervical cancer treatment
Knowledge-focused OngoingAlthough significant advances in screening and treatment , cervical cancer is the fifth most common female cancer in Europe. Major prognostic factors for oncological outcome are used to categorise patients at high, intermediate and low risk groups and to define the type of radica…
Sponsor: University of Campania Luigi Vanvitelli • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Two quick zaps: new radiation approach aims to cut prostate cancer treatment time
Disease control Recruiting nowPhase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer. The primary purpo…
Phase 1 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC